The Medicines and Healthcare products Regulatory Agency (MHRA) has published the minutes of its 2026 annual accountability review — the formal ministerial assessment of the regulator's performance and priorities. While the review covers the full breadth of MHRA activity, several areas directly affect community and hospital pharmacy practice across the UK.
What is the MHRA accountability review?
The annual accountability review is the mechanism by which government ministers assess MHRA's delivery against its strategic objectives. The review examines regulatory performance across medicines licensing, medical devices, clinical trials oversight and safety surveillance.
Published as a transparency data release on gov.uk, the minutes provide insight into the regulator's current priorities and where resource is being directed.
Key areas relevant to pharmacy
Medicines supply and shortages
Medicine shortages remain one of the most operationally challenging issues for community pharmacists. The MHRA plays a role in authorising alternative supply arrangements — including Serious Shortage Protocols (SSPs) and import licences — when standard supply chains fail.
According to PharmSee's tracking of 1,765 active pharmacy vacancies across England, none specifically mention supply chain management in their job descriptions, yet managing shortages is a daily reality for dispensing teams. The MHRA's continued focus on supply resilience has direct implications for workload at the pharmacy counter.
Yellow Card reporting
The MHRA's Yellow Card scheme — the UK's system for reporting suspected adverse drug reactions — relies heavily on pharmacy professionals. Community pharmacists are among the most frequent reporters outside hospital settings.
The accountability review examines reporting volumes and signal detection performance. For pharmacists, this reinforces the professional obligation to report suspected ADRs, particularly for newly marketed medicines (identified by the Black Triangle symbol ▼). PharmSee's guide to Yellow Card reporting covers the process in detail.
Medical device regulation
Following the UK's departure from the EU, the MHRA has been developing the UK's independent medical device regulatory framework. This affects pharmacy in several ways:
- Blood glucose monitors dispensed to diabetic patients
- Peak flow meters supplied to asthma patients
- Blood pressure monitors used in pharmacy screening services
- COVID-19 and lateral flow tests still available over the counter
The accountability review assesses progress on the new UK Conformity Assessment (UKCA) marking regime, which will eventually replace CE marking for medical devices sold in the UK.
Clinical trials regulation
The MHRA oversees clinical trial authorisation in the UK. As covered in PharmSee's recent article on the government's 150-day clinical trial target, the regulator's efficiency in processing trial applications directly affects investigational pharmacy workload in hospital settings.
How the MHRA affects day-to-day pharmacy practice
While the MHRA is not the pharmacy profession's direct regulator — that role belongs to the General Pharmaceutical Council (GPhC) — its decisions shape what pharmacists can supply, how they report safety concerns and which products reach pharmacy shelves.
| MHRA function | Pharmacy impact |
|---|---|
| Marketing authorisations (new medicines) | Determines what can be dispensed |
| Reclassification (POM → P → GSL) | Expands or restricts OTC supply |
| Drug safety alerts | Requires pharmacist action (recalls, supply changes) |
| Serious Shortage Protocols | Authorises therapeutic substitution during shortages |
| Yellow Card scheme | Professional reporting obligation |
| Medical device regulation | Affects devices sold/supplied in pharmacy |
What pharmacists should take from this review
The accountability review is a high-level governance document, not an operational manual. But it signals where regulatory attention is focused — and that focus filters down to pharmacy practice through:
- Updated safety alerts and field safety notices
- Changes to licensing conditions that affect dispensing
- New or revised guidance on medicine supply during shortages
- Evolving expectations around adverse reaction reporting
Pharmacists looking to stay current on MHRA developments can monitor the gov.uk MHRA publications page and sign up for Drug Safety Update emails.
For pharmacy professionals exploring career opportunities in regulatory or safety roles, PharmSee's job search tracks vacancies across 11 pharmacy employers in England.
Sources
- Gov.uk, MHRA annual accountability review minutes (15 April 2026)
- MHRA, About us — role and responsibilities
- PharmSee vacancy data, 15 April 2026 (1,765 active roles across 11 sources)